Inventiva to Present Two Studies on Lanifibranor at EASL Congress 2026
Inventiva, a biopharmaceutical company specializing in the development of oral therapies for metabolic dysfunction-associated steatohepatitis (MASH), announces the presentation of two abstracts at the annual European Association for the Study of the Liver (EASL Congress 2026), which will be held from May 27 to May 30, 2026, in Barcelona.
Two Poster Presentations on the Effects of Lanifibranor
The first abstract, titled 'Lanifibranor-induced improvements in histological parameters and cardiometabolic markers in MASH are independent of weight change and closely associated with adiponectin induction' (number FRI-189), will be presented as a poster on May 29, 2026. It is authored by Mary E Rinella, Guillaume Wettstein, Philippe Huot-Marchand, Jason Campagna, Sven Francque, and Manal F. Abdelmalek. The second abstract, 'Ultrastructural assessment of liver sinusoidal endothelial cell capillarisation in metabolic-dysfunction associated steatotic liver disease and its modulation by lanifibranor' (number SAT-117-YI), will also be presented as a poster on May 30, 2026. This presentation includes fourteen authors, among them Guillaume Wettstein and Sven M. Francque.
Lanifibranor, a Pan-PPAR Agonist in Clinical Development
Lanifibranor is a small molecule administered orally designed to activate all three isoforms of PPAR (peroxisome proliferators). It induces anti-fibrotic, anti-inflammatory effects as well as positive vascular and metabolic changes. Inventiva believes that its moderate and balanced pan-PPAR modulator profile contributes to the good safety and tolerance profile observed in clinical trials and preclinical studies. The U.S. FDA has granted 'Breakthrough Therapy' and 'Fast Track' statuses to lanifibranor for the treatment of MASH. The drug candidate is currently being evaluated in the pivotal Phase 3 NATiV3 clinical study for the treatment of adult patients with MASH. Inventiva will also be present at the congress at booth number 35.
